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We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic
colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of
these patients. Forty patients received modified FOLFIRI: irinotecan 180mgm
 2, day 1; folinic acid, 200mgm
 2; and 5-fluorouracil: as
a 400mgm
 2 bolus, days 1 and 2, and a 48-h continuous infusion 1200mgm
 2, from day 1. Treatment was repeated every 2 weeks,
with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen
(47.5%) of 40 patients achieved an objective response; 13 (33%) underwent resection. After a median follow-up of 56 months,
median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for
resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median
disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight
were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved
favourable survival times.
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Worldwide, colorectal cancer (CRC) is the fourth most common
malignancy in men and the third most common in women. In
2002, the disease accounted for more than one million new cancer
cases and caused 528978 deaths (Parkin et al, 2005). Approxi-
mately 25% of CRC patients present with metastatic disease, with
the liver being the most common site of metastasis. Over time,
40–50% of newly diagnosed CRC patients will develop metastatic
disease (Saltz et al, 2000). The 5-year survival rate for patients with
metastatic CRC (mCRC) is 5–30% (Van Cutsem et al, 2005).
Patients who are able to undergo resection of isolated liver
metastases have the chance of cure or improved survival. If cases
are carefully selected for surgery, the 5-year survival rate may be as
high as 60% (Fernandez et al, 2004; Pawlik et al, 2005). However,
only 10–20% of patients with mCRC are suitable for liver resection
at presentation (Adam, 2003). Over the last 10 years, the
introduction of two new active cytotoxic chemotherapy drugs
and several targeted biological agents has improved the outlook for
patients with mCRC. Median survival times in excess of 20 months
can now be expected with the first- and second-line use of
irinotecan and/or oxaliplatin in combination with 5-fluorouracil
(5-FU)/folinic acid (FA). This compares favourably with the 12–14
months previously achieved with 5-FU/FA alone (Douillard et al,
2000; Thirion et al, 2004).
These more active chemotherapy regimens are also associated
with higher response rates of 39–62% (Bismuth et al, 1996;
Douillard et al, 2000; Saltz et al, 2000; Tournigand et al, 2004;
Alberts et al, 2005; Kohne et al, 2005). In addition, as many as 68%
of responding patients with initially unresectable liver disease have
been reported to be subsequently eligible for secondary resection
of their metastases (Alberts et al, 2005). Indeed, the importance of
maximising response rates in this setting was highlighted by the
retrospective analysis of Folprecht et al (2005), which demon-
strated a strong correlation between response and resection rates,
especially in selected patients with no disease outside the liver.
The present study previously reported that 32.7% of patients
with CRC were able to undergo potentially curative surgical
resection of initially unresectable liver metastases following
neoadjuvant chemotherapy with an irinotecan/5-FU/FA combina-
tion (modified FOLFIRI) (Pozzo et al, 2004). This paper reports on
the long-term follow-up of these patients, providing data on
overall survival, disease-free (DF) survival and time to progression
(TTP).
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Patients
Patients aged 18–75 years with unresectable colorectal liver
metastases were eligible for entry into the study. Other eligibility
criteria were no evidence of extrahepatic disease or involvement of
more than 70% of the liver; Eastern Cooperative Oncology Group
(ECOG) performance status of 2 or less; no previous chemotherapy
for advanced disease; any adjuvant chemotherapy completed at
least 6 months prior to study entry; no history of other
malignancies; adequate bone marrow (WBC 43 10
9l
 1, platelets
4100 10
9l
 1, haemoglobin 410gdl
 1), liver (total bilirubin
o2mgdl
 1, aspartate aminotransferase or alanine aminotransfer-
ase o3 upper limit of normal) and renal function (blood urea
nitrogen p30mgdl
 1, creatinine clearance 460mlmin
 1, serum
creatinine p1.5mgdl
 1); and a life expectancy of more than 3
months. Written informed consent was provided by all patients.
Chemotherapy
Modified FOLFIRI was administered every 2 weeks and consisted
of the following: irinotecan 180mgm
 2 given i.v. on day 1; 5-FU
1200mgm
 2 continuous i.v. infusion over 48h from day 1; FA
200mgm
 2 i.v. on days 1 and 2 and 5-FU 400mgm
 2 i.v. bolus on
days 1 and 2. Response was assessed every 12 weeks (six cycles). In
cases of neutropaenia (p1.5 10
9l
 1), thrombocytopaenia
(p100 10
9l
 1) or significant non-haematologic toxicity, treat-
ment was delayed for 1 week. In the event of grade 3/4
neutropaenia or diarrhoea, the doses of irinotecan and 5-FU were
reduced by 25%. The dose of 5-FU only was similarly reduced in
the event of grade 3/4 stomatitis. Treatment was interrupted for
grade 4 haematologic toxicity or grade 4 gastrointestinal toxicity
(lasting 41 week after a previous dose reduction or a delay in dose
administration of 42 weeks).
Chemotherapy was continued until an objective response was
achieved (indicating suitability for surgery), or until disease
progression or unacceptable toxicity. Those patients who under-
went resection of their liver metastases received six further cycles
of the same chemotherapy regimen postoperatively. Patients with
progressive disease were treated at the discretion of the
investigator.
Assessments
Initial unresectability of liver metastases was assessed as described
previously, using the criteria set out by the institution at which the
study was carried out (Pozzo et al, 2004).
RESULTS
Patients
Forty patients were enrolled into the study over 2.5 years up to
January 2003. The patients’ baseline characteristics are outlined in
Table 1. The median age of the patients was 58.7 years (range: 32–
75 years) and the majority were male (60%). All but one patient
had an ECOG performance status of 0. The majority of patients
(67.5%) had synchronous metastases, with the remainder being
metachronous. At study entry, 21 patients (52.5%) had less than
three metastases and 11 (27.5%) had more than six. Twelve (30%)
patients had at least one lesion X5cm in diameter and seven
(17.5%) patients had metastases that were unfavourably located in
the hilum.
Of those patients with liver metastases that were considered to
be unresectable, 35% had large numbers of metastases, 25% had
large metastases, 5% had inadequate liver reserve and 35% had
surgically inaccessible metastases (Table 1).
Response to chemotherapy
As of December 10 2006, median follow-up was 56 months. All 40
patients had been evaluated for response yielding an objective
response rate of 47.5%, including two complete responses. Of
the 19 (47.5%) patients who experienced an overall response, 16
were considered to be eligible for surgery (after a median of eight
cycles of chemotherapy per patient (range: 6–12)) and 13
underwent resection of their liver metastases. The median overall
survival of these patients has not yet been reached. The median
survival for all 40 patients was 31.5 months (Figure 1A) and in
non-resected patients, 24 months (Table 2). Nine out of 40 patients
(22.5% (95% CI: 10.5–34.5%)) were still alive, including one not
resected patient. The median TTP for all patients was 14.3 months
(range: 2–49), and in non-resected patients, 5.2 months.
Adverse events
The treatment was well tolerated and the adverse events that were
observed and described previously were those typical of the
cytotoxic agents used (Pozzo et al, 2004). There were no delayed
onset adverse events. There were no significant differences in the
incidence and severity of adverse events experienced by patients
during the additional postresection chemotherapy phase compared
with those reported for the initial phase of treatment.
Surgery
Among the 13 patients who underwent surgery, there were 13 R0
liver resections. Most of these patients (10 out of 13) underwent
multiple segmental resections. As reported previously, the resec-
tion rate following chemotherapy was highest in those patients
with large (45cm) metastases (6 out of 10) (Pozzo et al, 2004).
Table 1 Baseline characteristics of patients
Characteristic n¼40 patients
Gender (%)
Male 60
Female 40
Median age, years (range) 58.7 (32–75)
ECOG performance status (%)
0 97.5
1–2 2.5
Metastases (%)
Synchronous 67.5
Metachronous 32.5
Number of metastases (%)
o3 52.5
3–6 20
46 27.5
Largest metastasis (%)
X5cm diameter 30
o5cm diameter 70
Site of metastasis (%)
Hilum 17.5
Other sites 82.5
Main cause of unresectability (%)
Number of metastases 35
Location of metastases 35
Size of metastasis 25
Insufficient liver reserve 5
ECOG¼Eastern Cooperative Oncology Group.
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following surgery. One patient experienced anaemia as a
consequence of postoperative bleeding (Pozzo et al, 2004).
Disease-free survival
The median DF survival of the resected patients was 52.5 months
(Figure 1B). At the time of reporting, a median of 56 months from
resection, 6 (46% (95% CI: 19.3–72.9%)) of the 13 radically
resected patients were still disease free and 8 (62%) of the 13 were
still alive (Table 2).
DISCUSSION
After a median follow-up period of nearly 60 months, the median
survival for all patients was 31.5 months. This is one of the highest
reported median survival times for a prospective study in similar
groups of patients treated with standard combinations of cytotoxic
agents. Moreover, currently, the median survival time for those
patients who underwent secondary resections of their liver
metastases has not yet been reached.
It has been recognised for some time that resection of liver
metastases offers the best long-term hope for patients with mCRC.
Chemotherapy regimens combining 5-FU/FA with irinotecan and/
or oxaliplatin have demonstrated impressive efficacy in the
downstaging of liver metastases to permit secondary resection
(Van Cutsem et al, 2005) and their role in the neoadjuvant setting
is now essentially undisputed. However, as yet, there is no
consensus about which neoadjuvant regimen will be the most
effective, either in general terms or for particular patients (as
defined by disease or genotypic variation). Emerging data suggest
that the addition of targeted biological agents to such regimens will
further improve efficacy. Indeed, Folprecht et al (2006) reported a
median survival time of 33 months, using cetuximab, an EGFR-
targeted monoclonal antibody, in combination with irinotecan/5-
FU/FA. In a randomised phase III trial, cetuximab was shown to
increase response rate, progression-free survival and resection rate
over FOLFIRI alone in patients with advanced CRC, with the PFS
benefit being greatest for those patients with liver-only metastases
(Van Cutsem et al, 2007).
One of the factors that have hindered comparisons between
studies of neoadjuvant treatment of initially unresectable colo-
rectal liver metastases is that there is no universally accepted
definition of unresectability. Patient selection is a crucial factor,
both for maximising the benefits achievable from primary
resection (Fong et al, 1999) and for enabling the highest resection
rates following neoadjuvant therapy (Adam et al, 2004a,b;
Folprecht et al, 2005). In their retrospective analysis, Folprecht
et al (2005) found that in studies which enrolled patients with
metastases confined to the liver, 24–54% of patients were able to
undergo resection of their metastases subsequent to chemo-
therapy, whereas only 1–26% of patients in non-selective trials
(patients with hepatic or extrahepatic disease) became eligible for
secondary surgery. However, this analysis found a strong
correlation between the response rate to neoadjuvant therapy
and the resection rate in both the selected (r¼0.96, P¼0.002) and
unselected (r¼0.74, Po0.001) patients.
Studies of resection following neoadjuvant therapy have also
demonstrated long-term benefits. Giacchetti et al (1999) reported
that 77 out of 151 (51%) patients had surgery with curative intent
following neoadjuvant treatment with 5-FU/FA/oxaliplatin. Com-
plete resection was achieved in 58 patients. The median survival of
the operated patients was 48 months (range: 25–71), and the 5-
year survival rate was 50% (range: 38–61). A more recent
retrospective analysis by Zaniboni et al (2005) of oxaliplatin-
based chemotherapy found an overall response rate of 78.5% in
105 patients. Ninety-nine patients had liver surgery, with 79%
undergoing radical resection. The median survival time for these
patients was 42 months.
In a study using a neoadjuvant combination of 5-FU/FA/
irinotecan/oxaliplatin (FOLFOXIRI) (Masi et al, 2006), there was a
response rate of 72% in unselected patients and a 26% (19
patients) hepatic resection rate. In five patients, extrahepatic
disease was also resected. The median overall survival of surgical
patients was 36.8 months, with a 4-year survival rate of 37%. The
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Figure 1 (A) Median overall survival. (B) Median disease-free survival.
Table 2 Survival and time to progression in resected and non-resected
patients
All patients
n¼40
Non-resected
patients n¼27
Resected patients
n¼13
Median survival,
months (range)
31.5 (4–92) 24 NR
Median TTP,
months (range)
14.3 (2–49) 5.2 (2–13) 52.5
Median DF
survival, months
(range)
— — 52.5 (2–89)
Survival (%)
6 months 97.5 96.2 100 (85% DF)
1-year follow-up 87.5 81.4 100 (77% DF)
2-year follow-up 63.5 55.5 100 (62% DF)
Last follow-up
(5 years)
22.5 3.7 62 (46% DF)
(95% CI: 10.5, 34.5) (OS 95% CI: 19.3, 72.9)
(DF 95% CI: 19.3, 72.9)
CI¼confidence interval; DF, disease-free; NR¼not reached; OS¼overall survival;
TTP¼time to progression.
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soverall survival of patients who responded to chemotherapy but
did not undergo surgery was 22.2 months (P¼0.0114). In a
randomised phase III trial, FOLFOXIRI improved response rate,
progression-free and overall survival compared with FOLFIRI,
with secondary R0 resection rates of 15 vs 6% in non-selected
patients and 36 vs 12% in patients with metastases confined to the
liver (Falcone et al, 2007).
A multicentre phase II study investigated the use of irinotecan
with 5-FU/FA (FOLFIRI) as neoadjuvant chemotherapy in selected
patients with unresectable liver metastases (Ho et al, 2005). The
overall response rate was 55% (22 out of 40 patients: 95% CI: 39.5–
70.4%). Median overall survival was 20 months (95% CI: 17.7–
26.6). Four patients underwent resection of metastases and
remained alive at a median follow-up time of 33 months.
In the current study, neoadjuvant treatment with FOLFIRI
achieved a response rate of 47.5%, with one-third of patients able
to undergo secondary resection of liver metastases. Following
resection, patients achieved a worthwhile median DF survival of
52.5 months. Median survival (all patients) was 31.5 months after a
median follow-up of 56.0 months, and will be higher in radically
resected patients, the median survival not yet having been reached.
This compares favourably with Ho et al (2005) and other phase II
studies in patients with initially unresectable metastases confined
to the liver (Folprecht et al, 2005) and confirms the benefit of
perioperative chemotherapy demonstrated in the EORTC EPOC
trial in patients with resectable liver metastases (Nordlinger et al,
2007). Furthermore, the median overall survival is approaching
twice that for unselected, unresected patients reported for
combination therapy in the FOCUS (Seymour et al, 2007) and
CAIRO trials (Punt et al, 2007).
As the use of neoadjuvant therapy has increased, so has the
concern about possible long-term adverse effects of chemotherapy,
particularly on the liver, where there is some evidence of vascular
changes (Rubbia-Brandt et al, 2004; Adam et al, 2005) and
steatohepatitis (Fernandez et al, 2005) following chemotherapy.
However, although the vascular changes may increase the risk of
intraoperative bleeding, it is not thought that they have any
significant clinical impact (Adam et al, 2005).
Also, a retrospective study by Karoui et al (2006) showed that
although preoperative chemotherapy was significantly associated
with sinusoidal dilatation, atrophy of hepatocytes and/or hepato-
cytic necrosis (49 vs 25%, P¼0.005) and increased morbidity, it
did not appear to be linked to increased postoperative mortality in
those patients who were resected. It is now generally accepted that
provided patients are not overtreated with chemotherapy prior to
surgery, there is little evidence of increased mortality and
morbidity.
Ideally, the overall survival benefit conferred by neoadjuvant
treatment needs to be validated in a prospective randomised trial
in the palliative setting. Such a trial, in the light of present
knowledge, would be ethically unacceptable because it should
include a no surgery arm in which patients would not undergo
surgery, even if their liver metastases become resectable after
chemotherapy. However, prolonged (5 years or more) follow-up of
patients, with identification of the particular regimen used to
facilitate the resection of liver metastases, may be all that is
necessary to fully evaluate the benefits of the different neoadjuvant
treatment choices.
What is clear from the results of the current study is that
irinotecan combination therapy (FOLFIRI) should be considered
for the neoadjuvant treatment of patients with mCRC who
have unresectable liver metastases as part of current strategic
patient management practices. Future large-scale randomised
studies in this setting should therefore include, for comparison,
arms that receive irinotecan-based chemotherapy. Additionally,
conventional chemotherapy could be combined with one or
more molecularly targeted drugs as soon as the data on
their role in advanced disease become available (Van Cutsem
et al, 2007).
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